Curcumol triggers apoptosis of p53 mutant triple-negative human breast cancer MDA-MB 231 cells via activation of p73 and PUMA

LANZHEN HUANG¹, ANG LI¹, GUANZHEN LIAO¹, FEICHENG YANG¹, JING YANG¹, XU CHEN² and XIAOSHAN JIANG¹³

¹Center for Science Research; ²School of Pharmacy; and ³Graduate College, Guilin Medical University, Guilin, Guangxi 541004, P.R. China

Received August 21, 2015; Accepted March 7, 2017

DOI: 10.3892/ol.2017.6273

Abstract. Triple-negative breast cancer (TNBC; estrogen receptor-negative, progesterone receptor-negative and Her-2-negative) is often accompanied by a higher frequency of p53 gene mutations. Therefore, TNBC is challenging to treat due to a lack of biological targets and a poor sensitivity to conventional therapies. Curcumol is a monomer composition isolated from the ethanol extracts of Curcuma wenyujin, a Chinese medicinal herb traditionally used as a cancer remedy. Previous studies have revealed that curcumol is able to block proliferation in various human tumor cell lines. However, the underlying mechanisms have yet to be elucidated. The present study aimed to investigate the anticancer effects of curcumol in the human p53 mutant TNBC MDA-MB-231 cell line and its underlying mechanisms. Cell viability and growth were determined by MTT and a mice xenograft model assay, respectively. Cell cycle distribution was examined by flow cytometry. Apoptosis was evaluated by apoptotic morphology analysis with DAPI staining. The protein expression in cells was evaluated by immunoblotting. Treatment of MDA-MB-231 cells with curcumol resulted in a significant inhibition of cell proliferation in vitro [half maximal inhibitory concentration (IC₅₀)=240.7±85.0 µg/ml for 48 h and IC₅₀=100.2±13.5 µg/ml for 72 h]. Curcumol treatment also resulted in the suppression of xenograft growth in vivo (100 or 200 µg/kg for 21 days), as well as G1 phase arrest and an apoptotic response, which were accompanied by the upregulation of p73 expression and the activation of the expression of p53 upregulated modulator of apoptosis (PUMA) and Bcl-2 antagonistic killer (Bak). No cleavage of poly (ADP-ribose) polymerase was detected. To the best of our knowledge, the present data demonstrate for the first time that curcumol inhibits the growth of MDA-MB-231 cells and triggers p53-independent apoptosis, which may be mediated by the p73-PUMA/Bak signaling pathway. Curcumol may, therefore, be a potential compound for use in the development of novel TNBC therapeutics.

Introduction

Triple-negative breast cancer (TNBC; estrogen receptor-negative, progesterone receptor-negative and Her-2-negative) remains challenging to treat due to the innate aggressive biological characteristics and the lack of effective therapies (1,2). TNBCs represent ~15% of all breast cancer cases and are often accompanied by a higher frequency of p53 gene mutations (2,3). The tumor suppressor gene p53 serves a critical role in conferring cancer cell sensitivity to DNA-damaging agents (3). Failure of p53 signaling leads to resistance to chemotherapies (3-5). p73 is a member of the p53 gene family. Under certain conditions, p73 is able to replace the p53 function in response to DNA damage, activate the transcription of p53-responsive genes and inhibit cell growth in a p53-like manner by inducing cell cycle arrest and apoptosis (6-8). Therefore, the identification of anticancer drugs able to activate p73 and target p53 downstream genes may provide a chemotherapy approach for the treatment of p53-deficient types of cancer.

Curcuma is a traditional Chinese herbal medicine, which may be subgrouped into Curcuma aeruginosa Roxb and Curcuma wenyujin Y. H. Chen et C. Ling (Curcuma wenyujin). Curcuma is traditionally used to treat various ailments, including cacochylia, traumatic hematoma, parasitic infection and tumors. The essential oils of Curcuma wenyujin exhibit antitumor, anti-inflammatory, antioxidant and antimicrobial characteristics with low cytotoxicity and are embodied in the official Pharmacopoeia of the P.R. China as an anticancer and antiviral remedy (10,11). A total of six volatile compounds (curdione, curcumol, germancrome, curzerene, 1,8-cineole and β-elemene) have been successfully isolated from the essential oil of Curcuma wenyujin (12). As one of the major components of the essential oil, curcumol,

Correspondence to: Dr Xiaoshan Jiang, Graduate College, Guilin Medical University, Hong-De Building, 109 North 2nd Huan-Cheng Road, Guilin, Guangxi 541004, P.R. China
E-mail: jiangxs@glmc.edu.cn

Abbreviations: IC₅₀, half maximal inhibitory concentration; PI, propidium iodide; PUMA, p53 upregulated modulator of apoptosis; TNBC, triple-negative breast cancer

Key words: curcumol, apoptosis, anticancer, p73, PUMA, breast cancer, MDA-MB-231
Materials and methods

Animals, cell lines and materials. In total of 24 female 4-week-old BALB/c nu/nu (nude) mice (~15 g) were purchased from the Experimental Animal Centre of the Shanghai Institutes for Biological Sciences (Shanghai, China) and raised in SPF conditions; the experimental protocol of the present study was approved by the Guilin Medical University Ethics Committee for Animal Experimentation (Guilin, China). The MDA-MB-231 and MCF-7 cell lines was donated by the Experimental Animal Centre of the Shanghai Institute of Parasitic Disease, Shanghai, China. A total of 1x10^6 TNBC MDA-MB-231 cells were suspended in 0.2 ml PBS and injected subcutaneously into the right flank of the nude mice. The mice were intraperitoneally injected with curcumol (100 or 200 µg/kg) every 48 h after developing measurable tumors. The tumor growth was monitored every 3 days and the mice were sacrificed by cervical dislocation on the 21st day subsequent to i.p. injection. Tumors were then dissected and weighed.

Cell cycle analysis. TNBC MDA-MB-231 cells were seeded in 6 cm (diameter) dishes, synchronized by serum deprivation at 37°C for 96 h. Cells were then exposed to 25 or 100 µg/ml curcumol for 20 and 24 h, respectively, at 37°C. Cells treated with an equal volume of ethanol at 37°C were used as a control. At the designated time points (20 and 24 h after exposure to curcumol), adherent cells were harvested by trypsinization and floating cells were collected by centrifugation (3,000 x g, 5 min, room temperature). Cells were fixed in 70% ethanol and the absorbance was measured at 510 nm using an iMark microplate absorbance reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). All assays were performed in quadruplicate and each experiment was conducted five times. Cell inhibition was calculated using the following formula: Inhibition rate (%)=[1-(OD test/OD control)]x100. Optical density (OD) represents the absorbance value. The half maximal inhibitory concentration (IC_{50}) was calculated using SPSS version 20.0 (IBM SPSS, Armonk, NY, USA).

Xenograft model assay. BALB/c nu/nu mice were randomly assigned into three groups with eight mice per group, and maintained in the specific-pathogen-free Animal Facility at Guilin Medical University. A total of 1x10^7 TNBC MDA-MB-231 cells were suspended in 0.2 ml PBS and injected subcutaneously into the right flank of the nude mice. The mice were intraperitoneally injected with curcumol (100 or 200 µg/kg) every 48 h after developing measurable tumors. The tumor growth was monitored every 3 days and the mice were sacrificed by cervical dislocation on the 21st day subsequent to i.p. injection. Tumors were then dissected and weighed.

Cell culture. The TNBC MDA-MB-231 cell line was cultured in Dulbecco’s modified Eagle’s medium (HyClone; GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), 100 µg/ml streptomycin and 100 U/ml penicillin (HyClone; GE Healthcare Life Sciences) at 37°C in a humidified atmosphere containing 5% CO₂. When cells were ~50% subconfluent, the cells were treated with 12.5-800 µg/ml of curcumol (100 mg/ml dissolved in ethanol). Untreated MDA-MB-231 cells served as a control and were cultured following a similar protocol in medium supplemented with equivalent volumes of ethanol (vehicle).
The experiment was performed in triplicate.

Morphological analyses. TNBC MDA-MB-231 cells were seeded onto 6-well plates containing microscope coverslips at a density of 4x10^5 cells/well. Following an overnight incubation at 37°C, cells were treated with 50, 100 or 200 µg/ml curcuminol or with the matched ethanol vehicle and incubated for an additional 48 h at 37°C. Cells were then fixed in 0.4% PBS-buffered paraformaldehyde solution for 15 min, stained with DAPI for 5 min at room temperature and mounted on microscope slides. The morphology of the cell nuclei was observed at an excitation wavelength of 350 nm using a laser confocal fluorescence microscope (LSM710 Meta; Carl Zeiss AG, Oberkochen, Germany). The percentage of apoptotic cells (cells with nuclear condensation and/or fragmentation) was evaluated by randomly counting ≥10 fields for each condition.

Annexin V/PI-staining. MDA-MB-231 cells were seeded onto 6-well plates at a density of 4x10^5 cells/well. After 24 h, cells were treated with 50, 100 and 200 µg/ml curcuminol. Following 18, 24 or 36 h exposure to curcuminol, the cells were collected and analyzed using the Annexin V-FITC Apoptosis Detection kit (BD Biosciences) according to the manufacturer's instructions. Briefly, the cells were trypsinized, washed with PBS and resuspended in 100 µl buffer solution (10 mM Hepes/NaOH at pH 7.4, 140 mM NaCl, 2.5 mM CaCl_2) at a final concentration of 1x10^6 cells/ml. The cells were incubated with 5 µl Annexin V-FITC for 15 min at room temperature without light exposure. Subsequent to the addition of 5 µl PI, flow cytometry was immediately performed using the FACSAria™ III system. A total of 10,000 ungated events were acquired for each sample; the data were analyzed with FACSDiva® (version 6.1.3; BD Biosciences).

Protein extraction and immunoblotting. Cells were treated with 25 or 100 µg/ml curcuminol or vehicle for 24 h. Following incubation at 37°C for 24 h, floating and adherent cells were collected and lysed for 30 min on ice in radioimmunoprecipitation assay buffer (150 mM sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-pH 8.0) added with 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin and 2 µg/ml aprotinin (Sigma-Aldrich; Merck KGaA). Samples were centrifuged at 10,000 x g at 4°C for 10 min and the supernatants were collected for immunoblotting according to a previously described method (18). In brief, cell lysates (50 µg protein/lane) were resolved in 8-10% SDS/PAGE gels and transferred to polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). Membranes were then incubated in a blocking buffer (5% nonfat milk in 20 mM Tris-HCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-pH 8.0) added with 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin and 2 µg/ml aprotinin (Sigma-Aldrich; Merck KGaA). Samples were centrifuged at 10,000 x g at 4°C for 10 min and the supernatants were collected for immunoblotting according to a previously described method (18). In brief, cell lysates (50 µg protein/lane) were resolved in 8-10% SDS/PAGE gels and transferred to polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). Membranes were then incubated in a blocking buffer (5% nonfat milk in 20 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20) for 1 h at room temperature and subsequently incubated with the aforementioned primary antibodies in the blocking buffer overnight at 4°C. Following washing with TBS buffer containing 0.1% Tween-20, the membranes were incubated with corresponding horseradish-peroxidase conjugated secondary antibodies (as aforementioned) at room temperature for 1 h. The blots were visualized by the use of the aforementioned enhanced chemiluminescent detection kit (Pierce; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The immunoblot bands were quantified by densitometry analysis using Scion Image 4.0 software (Scion Corporation, Frederick, MD, USA) and the signal intensity of each protein was normalized to the corresponding signal intensity of β-actin.

Figure 1. Suppression of TNBC MDA-MB 231 cell growth by curcuminol. (A) MTT assay demonstrated that the viability of MDA-MB-231 cells significantly decreased following treatment with curcuminol in a dose- and time-dependent manner. The results are representative of five independent experiments performed in quadruplicate. (B) Growth of MDA-MB-231 xenografts was inhibited by curcuminol. Mice with MDA-MB-231 xenografts were randomly divided into three groups (n=8) and treated intraperitoneally with curcuminol (100 and 200 µg/kg) or vehicle control every other day for 21 days. The mice were then sacrificed and the tumors were excised, weighed and images were captured. (C) The tumor weight comparison histogram of the control and curcumin treatment groups. Data are presented as the mean and the error bars represent the standard deviation. *P<0.05, **P<0.01 vs. vehicle control. TNBC, triple-negative breast cancer.
Statistical analysis. The results are presented as the mean ± standard deviation. One-way analysis of variance was used to evaluate overall difference between the groups. The Student's t-test was performed for pairwise comparison of normal distributed parameters. P<0.05 was considered to indicate a statistically significant difference.

Results

Curcumol suppresses the growth of TNBC MDA-MB-231 cells in vitro and in vivo. To the best of our knowledge, this is the first time that the effect of curcumol on TNBC MDA-MB-231 cell proliferation has been determined. The cells were treated with 12.5–800 µg/ml curcumol for 48 and 72 h, and cell viability was examined using an MTT assay. As presented in Fig. 1A, a significant dose- and time-dependent inhibition of TNBC MDA-MB-231 cell proliferation was observed when curcumol was administered at concentrations >25 µg/ml (P<0.05; P<0.01). The IC₅₀ value was 240.7±85.0 µg/ml for 48 h and 100.2±13.5 µg/ml for 72 h.

Although recent studies have suggested that curcumol may have anticancer properties, limited in vivo data has previously been presented. Therefore, the present study aimed to explore the effect of curcumol on TNBC MDA-MB-231 xenografts. Two groups of female BALB/C nude mice bearing TNBC MDA-MB 231 xenografts were intraperitoneally injected with curcumol (100 or 200 µg/kg) every other day for ≤21 days. Compared with the vehicle treatment group, the tumor volume was significantly reduced by ~90.4% in the 100 µg/kg (P=0.0024) of curcumol treatment group and by ~97.5% in the 200 µg/kg group (P=0.0009; Fig. 1B and C). Combined, these results suggest that curcumol is capable of blocking the growth of breast cancer TNBC MDA-MB-231 cells in vitro and in vivo.

Curcumol induces G₁ phase arrest and sub-G₁ phase cell accumulation. As the inhibition of cell proliferation may be

Figure 2. Induction of cell cycle arrest and sub-G₁ phase cell accumulation by curcumol in TNBC MDA-MB-231 cells. Following synchronization by serum starvation, MDA-MB-231 cells were stimulated by curcumol (25 and 100 µg/ml) or vehicle control for 20 or 24 h. 0 h was the point that cell population was released after the synchronization. Cells were harvested, fixed and stained with PI, and then analyzed for DNA content using flow cytometry. Flow cytometric plots include representative data and indicate that curcumol induced a G₁ phase arrest as well as an increase of sub-G₁ phase cells. The experiments were repeated ≥3 times and are also presented in Table I. PI, propidium iodide; TNBC, triple-negative breast cancer.
due to the arrest of cell growth, the present study investigated the regulatory effects of curcumin on the cell-cycle distribution in TNBC MDA-MB-231 cells. TNBC MDA-MB-231 cells were synchronized by serum starvation as aforementioned. The synchronized cells were stimulated with 25 or 100 µg/ml curcumin for 20 and 24 h at 37°C, respectively. The cells were then collected, stained with PI and subjected to flow cytometry analysis. The 0 h indicates the release point of synchronized cells. The results demonstrated a significant increase in the number of G1 phase cells, from 28.93-55.15% in the 100 µg/ml treatment group (P=0.0240), whereas there was only a slight elevation in the group of cells treated with 25 µg/ml curcumin (Fig. 2; Table I). Notably, when the cells were treated with a higher concentration of curcumin (100 µg/ml for 24 h), 41.44% of cells were observed to be in the hypodiploid sub-G1 phase, which suggested that the inhibitory effects of curcumin observed in TNBC MDA-MB-231 cells were associated with the induction of apoptosis.

Curcumin induces cell apoptosis. To confirm the aforementioned effect of curcumin on the TNBC MDA-MB-231 cells, the cellular apoptotic response was further investigated via two methodologies. Firstly, the apoptotic morphological features were investigated using DAPI staining. Following exposure to 50, 100 or 200 µg/ml curcumin for 48 h, TNBC MDA-MB-231 cells exhibited the following apoptosis-associated morphological changes: Nucleus shrinking, chromatin condensation and the formation of dot-shaped nuclear fragments (Fig. 3A and B). By contrast, the control group was observed to have fewer apoptotic cells.

The present study also confirmed and quantified the apoptotic cells using a flow cytometric Annexin V/PI double staining assay. In the quadrant dot plot of double variable flow cytometry, Q1 quadrant (Annexin V-/PI-) showed necrotic cells; Q2 quadrant (Annexin V+/PI-) stood for late apoptotic cells; Q3 quadrant (Annexin V-/PI+) showed living cells; and Q4 quadrant (Annexin V+/PI-) represented early apoptotic cells. As presented in Fig. 3C and D, treatment of TNBC MDA-MB-231 cells with 50, 100 or 200 µg/ml curcumin increased the early apoptotic cell population (Q4) from 1.8±0.95% (vehicle control) to 2.53±1.05% (50 µg/ml), 4.1±0.26% (100 µg/ml) and 12.93±5.9% (200 µg/ml), at 18 h; 4.1±2.6% (vehicle control) to 5.33±1.77% (50 µg/ml), 10±5.04% (100 µg/ml) and 22.5±1.58% (200 µg/ml) at 24 h; 4.2±2.31% (vehicle control) to 9.7±3.43% (50 µg/ml), 19.1±3.96% (100 µg/ml) and 27.13±6.42% (200 µg/ml) at 36 h. It also increased the late apoptotic cell population (Q2) from 5.96±3.2% (vehicle control) to 10.03±1.8% (50 µg/ml), 11.6±3.63% (100 µg/ml) and 15.9±13.09% (200 µg/ml) at 18 h; 3.93±1.55% (vehicle control) to 10.03±1.44% (50 µg/ml), 9.8±3.46% (100 µg/ml) and 16.83±5.43% (200 µg/ml) at 24 h; 7.66±1.35% (vehicle control) to 12.68±2.64% (50 µg/ml), 18.6±15.73% (100 µg/ml) and 24.4±12.34% (200 µg/ml) at 36 h. These results indicated that curcumin induces a marked level of apoptosis of TNBC MDA-MB-231 cells in a dose- and time-dependent manner.

Curcumin upregulates the expression of p73, PUMA and Bak. Previously published data have demonstrated that p73 may serve a critical role in the induction of cell death by apoptosis in various p53-deficient cancer cell lines, including TNBC 231 cells (7,19-21). In order to understand the events involved in curcumol-mediated apoptosis of TNBC MDA-MB-231-cells, the present study investigated the expression patterns of p73 as well as of the p53-mediated pro-apoptotic mediators PUMA and Bcl-2 associated X protein (Bax) gene family, using immunoblotting. MCF7 cells, which express wild-type p53 and exhibit overexpression of p53 and p21 following exposure to adriamycin (1 µM, 24 h) (22), were used as a positive control for the immunoblotting. As presented in Fig. 4, treatment with 25 µg/ml curcumin significantly increased p73 protein expression level (P=0.0016), and 100 µg/ml curcumin increased the levels of p73, Bak and PUMA proteins (P=0.0016, P=0.0263 and P=0.0093, respectively). No expression of p21 was detected, which confirmed the dysfunction of p53 in the TNBC MDA-MB-231 cells. The present study was unable to detect the cleaved band of PARP-1 protein in the cells treated with curcumin at the aforementioned dosages, which suggests a caspase-independent apoptosis pathway. Notably, there

Table I. Induction of G1 arrest and apoptosis in MDA-MB 231 cells by curcumol.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>G1</th>
<th>S</th>
<th>G2/M</th>
<th>Apoptosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 h</td>
<td>86.95±3.39</td>
<td>8.51±2.08</td>
<td>4.53±1.78</td>
<td>0.00±0.00</td>
</tr>
<tr>
<td>20 h</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>51.10±4.32</td>
<td>37.12±2.34</td>
<td>11.78±5.87</td>
<td>0.00±0.00</td>
</tr>
<tr>
<td>25.0 µg/ml</td>
<td>56.18±6.52</td>
<td>32.48±4.94</td>
<td>11.41±1.63</td>
<td>0.00±0.00</td>
</tr>
<tr>
<td>100.0 µg/ml</td>
<td>69.21±17.27</td>
<td>22.20±10.14</td>
<td>5.26±4.93</td>
<td>32.96±10.91b</td>
</tr>
<tr>
<td>24 h</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>28.93±12.34</td>
<td>50.01±9.54</td>
<td>1.01±11.25</td>
<td>0.00±0.00</td>
</tr>
<tr>
<td>25.0 µg/ml</td>
<td>33.28±21.35</td>
<td>48.09±13.90</td>
<td>18.64±11.44</td>
<td>0.00±0.00</td>
</tr>
<tr>
<td>100.0 µg/ml</td>
<td>55.15±10.32b</td>
<td>38.36±5.61</td>
<td>6.49±5.5</td>
<td>41.44±15.37b</td>
</tr>
</tbody>
</table>

Synchronized TNBC MDA-MB-231 cells were stimulated using curcumol (25 and 100 µg/ml) for 20 or 24 h, stained with propidium iodide and then the cell cycle distribution analyzed by flow cytometry. The 0 h indicates the release point of synchronized cells. The results are representative of three independent experiments, and data are presented as the mean ± standard deviation. (*P<0.05, **P<0.01 vs. vehicle control.)
was a 35.2% decrease of p53 expression detected in the cells treated with 100 µg/ml curcumol (P=0.0268; Fig. 4). These data suggest that curcumol-triggered apoptosis may occur via upregulation of the apoptotic proteins p73, PUMA and Bak and the downregulation of mutant p53 in TNBC MDA-MB 231 cells.

Discussion

Despite numerous advances in available cancer therapies, TNBC, a subgroup of breast cancer that is often accompanied with higher frequency of p53 gene mutations, remains a challenge in clinical practice due to the lack of biological targets and its resistance to chemo-radiotherapy (1-3). Natural products, particularly those obtained from medicinal herbs, including biochanin A, guercetin and curcumin, with apoptotic activity have attracted great attention as potential sources for the development of novel anticancer drugs (23-25). C. wenyujin, a Chinese traditional herbal medicine, has conventionally been used for the treatment of neoplasm and inflammatory diseases (9). An essential oil from C. wenyujin is listed as an anticancer and antiviral drug in the Pharmacopoeia of the P.R. China (11). Curcumol is one of the major pharmacological components of the aforementioned essential oil, and has recently been reported to exhibit an anti-proliferative effect on numerous human tumor cell lines, including lung, breast, ovary, liver, gastric and intestinal cancer (14-17). To the best of our knowledge, the present study is the first to provide evidence of the anticancer effect of curcumol in a p53 mutant TNBC MDA-MB-231 cell line, via demonstrating a direct inhibition of cellular viability and xenograft growth, and the induction of apoptosis.

Apoptosis serves an essential role in cell replacement, tissue remodeling and the removal of damaged cells under normal
conditions. The induction of apoptosis in malignant cells is becoming a practical strategy for cancer treatment (26,27). Thus, signaling pathways involved in enhancing apoptosis are potential targets for identifying innovative drug candidates.

There are a number of previous reports demonstrating that the oily extracts of C. wenyujin induce cellular apoptosis and inhibit proliferation in certain cancer cell lines (10,28-30). The present study focused on curcumol, one of the active compounds isolated from the curcuma oil (12). Data obtained from flow cytometry and cellular morphology studies demonstrate that curcumol is capable of inhibiting the growth of TNBC MDA-MB-231 cells in a predominantly apoptotic manner. These results are consistent with those observed in various other tumor cell lines (14-17). Furthermore, the present study supported the evidence indicating a marked effect of curcumol in a BALB/c nude mice xenograft model. Therefore, it is postulated that curcumol is capable of inducing apoptosis, which in turn causes tumor cell death.

There are multiple forms of apoptosis; two well-characterized apoptosis signaling pathways are the death receptor pathway and the mitochondrial pathway (31,33). In the death receptor pathway, the binding of death factors, including the Fas ligand, tumor necrosis factor (TNF) or TNF-related apoptosis-inducing ligand, to their corresponding receptors triggers a signaling cascade that results in the activation of initiator-caspase-8, which in turn activates the downstream effector caspase-3 leading to PARP cleavage (32). The mitochondrial pathway is initiated by BH3-only proteins that induce the activation and oligomerization of the Bcl-2 family members Bax and Bak (34). The oligomerized Bax/Bak then triggers the release of cytochrome c from mitochondria into the cytosol. Cytochrome c subsequently forms a complex with Apaf-1 and activates caspase-9 and caspase-3 (33,35). As a central integrator of apoptosis signaling pathways, mitochondria also release other pro-apoptotic factors, including apoptosis inducing factor (AIF), triggering a caspase-independent cell death in a Bcl-2-dependent manner (36). The tumor suppressor protein p53 mediates caspase-dependent and caspase-independent cell death through numerous signaling pathways, including the activation of Bcl-2 family member Bax, PUMA or AIF (37,38). The loss of p53 function typically results in the inhibition of apoptotic signaling pathways (39). p21 (CIP1/WAF1) is a regulator of cell cycle progression that is known to be directly activated by wild-type, but not mutant, p53. The lack of p21 expression may serve as an indicator for p53 dysfunction (40,41).

As hypothesized, the expression of p21 in MDA-MB-231 cells following treatment of curcumol was not detected in the present study, but a significant increase in p73 protein as well as an upregulation of PUMA and Bax expression was observed. p73 is a homolog of p53 and has a vital role in mediating apoptosis in a variety of p53 deficient cancer cells (42-44). In p73-induced apoptosis, p73 triggers the mitochondrial pathway by directly transactivating the Bax and PUMA promoters (42). PUMA belongs to the BH3-only subgroup of the Bcl-2 family. The expression of PUMA promotes the mitochondrial translocation of Bax and formation of the Bax/Bak complex, culminating in the induction of apoptosis (45). Notably, the cleaved band of the PARP-1 protein was not detected in the current study, suggesting that curcumol-induced apoptosis in TNBC MDA-MB-231 cells may be a caspase-independent method of cell death. Furthermore, Zhang et al (17) recently reported that curcumol induces caspase-independent apoptosis through the mitochondrial pathway in human ASTC-a-1 lung adenocarcinoma cells.

Figure 4. Upregulation of p73, PUMA and Bak expression by curcumol in TNBC MDA-MB-231 cells. (A) Immunoblotting demonstrated increased protein levels of p73, PUMA, Bak and cleaved PARP in MDA-MB-231 cells following treatment with 25 or 100 µg/ml curcumol for 24 h. Actin was the loading control, and ADM-treated MCF-7 cells served as the antibody controls. Cleavage of PARP is indicated by the arrow. (B) Quantitative data for the relative density of the proteins of interest. Each bar represents the mean ± standard deviation of three independent experiments (*P<0.05, **P<0.01 vs. the untreated control). PUMA, p53 upregulated modulator of apoptosis; Bak, Bcl-2 antagonistic killer; PARP, poly (ADP-ribose) polymerase; ADM, Adriamycin; MCF, macrophage chemotactic factor; TNBC, triple-negative breast cancer.
Notably, the present study observed a significant decrease in the expression levels of mutant p53 following curcumin treatment in TNBC MDA-MB-231 cells. Mutant p53 may not only lose tumor suppressive activity, but may also gain functions that promote malignant progression (46). The effect of the downregulation of mutant p53 protein expression may be associated with its anticancer properties.

The results of the present study have demonstrated the effects of curcumin, including directly suppressing the growth of human p53-mutant TNBC MDA-MB-231 cells via triggering apoptosis. The underlying mechanisms may include an enhancement of p73, which in turn transactivates the expression of PUMA and Bax, and inhibits mutant p53 expression. These results indicate that curcumin may be a promising anti-cancer compound for further investigation into novel cancer therapeutics, particularly for TNBC.

Acknowledgements

The present study was supported by the Guangxi Medical Science Research Center Fund (grant no. KJ2011-13) and the Guangxi Liver Damage and Repair Key Laboratory Fund (grant no. SYS201307).

References


